Related Experiment Video

Updated: Apr 12, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.9K

Intranasal sumatriptan for migraine in children

Ran D Goldman, Garth D Meckler

    Canadian Family Physician Medecin De Famille Canadien
    |May 15, 2015
    PubMed

    Insights

    Intranasal sumatriptan is a safe and effective abortive therapy for acute migraine headaches in children and adolescents. Recommended doses vary by weight, with larger trials needed to confirm efficacy.

    Area of Science:

    • Pediatric Neurology
    • Pharmacology

    Background:

    • Headaches, particularly migraine headaches, are increasingly diagnosed in pediatric populations.
    • Effective abortive treatments for pediatric migraines are crucial but often challenging to identify.

    Purpose of the Study:

    • To evaluate the efficacy and safety of intranasal sumatriptan as an abortive treatment for acute migraine headaches in children and adolescents.

    Main Methods:

    • Review of existing studies and clinical data on intranasal sumatriptan use in pediatric migraine patients.
    • Analysis of safety profiles and efficacy outcomes based on available evidence.

    Main Results:

    • Intranasal sumatriptan demonstrates a favorable safety profile in pediatric patients.
    • The treatment is considered mostly effective for acute migraine attacks in this age group.

    Conclusions:

    • Intranasal sumatriptan presents a viable therapeutic option for managing acute migraine headaches in children and adolescents.
    • Specific dosing recommendations include 20 mg for children >40 kg and 10 mg for those weighing 20-39 kg.
    • Further large-scale clinical trials are recommended to address limitations such as small sample sizes and potential placebo effects.
    Abstract

    More Related Videos

    Guidelines for Elective Pediatric Fiberoptic Intubation11:19

    Guidelines for Elective Pediatric Fiberoptic Intubation

    Published on: January 17, 2011

    18.9K
    Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery05:44

    Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

    Published on: November 14, 2018

    21.5K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    829
    Drug Delivery: Enteral Route01:18

    Drug Delivery: Enteral Route

    The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
    2.7K
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    868